

Delvys Rodriguez-Abreu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7423036/publications.pdf>

Version: 2024-02-01

99
papers

30,463
citations

100601

38
h-index

58552

86
g-index

101
all docs

101
docs citations

101
times ranked

24518
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	13.9	7,847
2	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2012, 13, 239-246.	5.1	4,943
3	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	13.9	4,701
4	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 2288-2301.	13.9	2,808
5	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
6	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	0.8	1,144
7	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
8	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 387-401.	5.2	704
9	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2020, 21, 1413-1422.	5.1	475
10	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
11	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	0.8	410
12	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1351-1360.	0.5	379
13	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1600-1609.	5.1	282
14	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021, 32, 881-895.	0.6	213
15	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1909-1924.	0.5	212
16	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208
17	Epidemiology of hematological malignancies. <i>Annals of Oncology</i> , 2007, 18, i3-i8.	0.6	201
18	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200

#	ARTICLE	IF	CITATIONS
19	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. Journal of Clinical Oncology, 2020, 38, 9503-9503.	0.8	179
20	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology, 2021, 39, 2327-2338.	0.8	146
21	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Journal of Clinical Oncology, 2022, 40, 2924-2933.	0.8	127
22	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 387-397.	5.1	119
23	Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Journal of Clinical Oncology, 2021, 39, 586-598.	0.8	117
24	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology, 2022, 17, 309-323.	0.5	114
25	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology, 2021, 16, 1883-1892.	0.5	93
26	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 1266-1276.	0.5	78
27	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clinical and Translational Radiation Oncology, 2018, 9, 5-11.	0.9	76
28	OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC. Journal of Thoracic Oncology, 2019, 14, S216-S217.	0.5	71
29	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer, 2020, 126, 4867-4877.	2.0	69
30	LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \geq 50%. Annals of Oncology, 2020, 31, S1181-S1182.	0.6	65
31	Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematological Oncology, 2008, 26, 8-20.	0.8	59
32	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS ONE, 2014, 9, e107200.	1.1	58
33	Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants, 2019, 8, 588.	2.2	57
34	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. Journal of Thoracic Oncology, 2019, 14, 2120-2132.	0.5	48
35	Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study. Final data of patients who underwent surgical assessment.. Journal of Clinical Oncology, 2019, 37, 8509-8509.	0.8	44
36	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clinical and Translational Oncology, 2015, 17, 1020-1029.	1.2	43

#	ARTICLE	IF	CITATIONS
37	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.. Journal of Clinical Oncology, 2017, 35, 9000-9000.	0.8	43
38	Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leukemia and Lymphoma, 2007, 48, 104-108.	0.6	41
39	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research, 2019, 8, 461-475.	1.3	38
40	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clinical and Translational Oncology, 2019, 21, 1270-1279.	1.2	38
41	Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Human Pathology, 2007, 38, 787-792.	1.1	34
42	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of Thoracic Oncology, 2020, 15, 1647-1656.	0.5	34
43	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 2019, 14, e0212813.	1.1	31
44	OA13.05 NADIM Study: Updated Clinical Research and Outcomes. Journal of Thoracic Oncology, 2019, 14, S241.	0.5	31
45	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
46	mRNA in exosomes as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. Oncotarget, 2017, 8, 50949-50957.	0.8	31
47	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clinical Cancer Research, 2021, 27, 5878-5890.	3.2	30
48	A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function. Clinical Cancer Research, 2008, 14, 7935-7939.	3.2	29
49	Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. , 2020, , .		29
50	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27
51	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. , 2021, 9, e002323.		26
52	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 2021, 11, e491.	1.7	26
53	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. Cancers, 2020, 12, 2178.	1.7	25
54	Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 102888-102897.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	0.6	17
56	Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. <i>PLoS ONE</i> , 2021, 16, e0251761.	1.1	17
57	Hepatitis C virus and GBVâ€C virus prevalence among patients with Bâ€cell lymphoma in different European regions: a caseâ€control study of the International Extranodal Lymphoma Study Group. <i>Hematological Oncology</i> , 2012, 30, 137-142.	0.8	16
58	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). <i>Lung Cancer</i> , 2020, 150, 62-69.	0.9	15
59	Lung cancer symptoms at diagnosis: results of a nationwide registry study. <i>ESMO Open</i> , 2020, 5, e001021.	2.0	15
60	Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. <i>Cancer Epidemiology</i> , 2020, 67, 101737.	0.8	15
61	Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 655-665.	0.4	15
62	Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2802.	1.8	14
63	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
64	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.	1.0	13
65	Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9533-9533.	0.8	13
66	Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. <i>Lung Cancer</i> , 2020, 147, 83-90.	0.9	12
67	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS â‰¥50%:â€Data from KEYNOTE-024. <i>Journal of Thoracic Oncology</i> , 2017, 12, S8-S9.	0.5	11
68	30 Immunotherapy in advanced NSCLCâ€from the â€tsunamiâ€™ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
69	Transformed follicular lymphoma in the rituximab era: A report from theSpanishLymphomaOncologyGroup. <i>Hematological Oncology</i> , 2019, 37, 143-150.	0.8	9
70	IMpower150: Exploratory analysis of brain metastases development.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9587-9587.	0.8	8
71	Are there differences by sex in lung cancer characteristics at diagnosis? â€a nationwide study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3902-3911.	1.3	8
72	Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous nonâ€small-cell lung cancer (NSCLC): LEAP-006.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9118-TPS9118.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. <i>Medicine (United States)</i> , 2017, 96, e9523.	0.4	6
74	Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
75	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. <i>BMC Cancer</i> , 2021, 21, 977.	1.1	5
76	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
77	Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. <i>Translational Lung Cancer Research</i> , 2021, 11, 0-0.	1.3	4
78	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	1.3	3
79	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4583.	1.0	3
80	The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. <i>Lung Cancer</i> , 2022, 164, 8-13.	0.9	3
81	SEOM clinical guidelines for the treatment of follicular non-Hodgkinâ€™s lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 760-764.	1.2	2
82	Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review. <i>Oncology and Therapy</i> , 2021, 9, 41-53.	1.0	2
83	Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). <i>Current Oncology</i> , 2021, 28, 1249-1255.	0.9	2
84	Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189. , 2021, , .		2
85	Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trialâ€™ Updated report on progression-free and overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9066-9066.	0.8	2
86	Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8019-8019.	0.8	2
87	Crizotinib in <i>ROS1</i>-rearranged lung cancer (EUCROSS): Updated overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9078-9078.	0.8	2
88	Neoadjuvant biweekly dose-dense chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 596-596.	0.8	1
89	EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer â€™ preliminary data on safety and tolerability.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20577-e20577.	0.8	1
90	Sex is a strong prognostic factor for overall survival in advanced non small cell lung cancer patients and should be considered for survival rates estimations.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20580-e20580.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	0.6	0
92	Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9528-9528.	0.8	0
93	PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9076-9076.	0.8	0
94	Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer. , 2012, , 81-94.		0
95	Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20026-e20026.	0.8	0
96	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21628-e21628.	0.8	0
97	Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9041-9041.	0.8	0
98	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. <i>Revista Espanola De Patologia</i> , 2020, 53, 140-148.	0.6	0
99	No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC. , 0, , .		0